

Invited Special Article

A Call for New Theories on the Pathogenesis and Pathophysiology of Endometriosis

The Endometriosis Initiative Group^{1*}

This group was formed out of the conviction that endometriosis research has not progressed at a pace in proportion to disease severity and the negative impact on women's quality of life. Furthermore, advancement in our understanding of this condition requires a quantum shift based on new theories of disease pathogenesis. With this conviction, this international group calls for new theories that may improve the understanding of this condition, leading to optimized management or even prevention. To facilitate this, a dedicated website serving as a repository where all proposed theories can be reviewed and critiqued by peers will be created.

Back to Square One

When preparing for the first World Congress on Endometriosis in November 1986, the primary goal of the scientific program committee was to understand the activity of the disease. Why does endometriosis affect some but not all women? Why does it progress in some but not all of those affected? At that time, genetic predisposition [1], abnormal peritoneal inflammation [2], altered hormonal responsiveness [3], and altered general immunity [4] were already considered as potential and promising research pathways. Excepting epigenetic aberrations [5,6], the stem cell hypothesis [7,8], and somatic mutations in both eutopic and ectopic endometrium [9–11], all the other possible mechanisms proposed to explain the presence of endometrial-like cells outside of the uterine cavity were already published, yet none of these putative mechanisms, which may occur in every woman, could individually explain why the disease occurs in some women but not others.

Nearly 4 decades later, minimally invasive surgery is the standard of surgical care, assisted reproductive technology has transformed the management of infertility, and imaging-enabled diagnosis of several subtypes of endometriosis has somewhat reduced the need for laparoscopy for diagnosis. Among 34 508 PubMed-indexed publications on endometriosis to date, the vast majority of them ($n = 29\ 601$ or 85.8%) were published after 1986 (<https://pubmed.ncbi.nlm.nih.gov/?term=endometriosis&sort=date>, accessed on January 17, 2024). However, treatment modalities of the disease are still limited to surgical excision, medically induced amenorrhea with or without hypoestrogenism, and symptomatic therapies such as nonsteroidal anti-inflammatory drugs and pelvic floor therapy. Recently, management based on patient reported outcome measures and experience of the disease was recommended to maximize the clinical benefits of these treatments [12].

Almost one century after Sampson proposed his retrograde menstruation theory [13], few know he also demonstrated the presence of “bits of endometrium” in uterine vessels during menses, already suggesting that a singular mechanism was not able to explain the variable clinical diseases associated with ectopic endometrium [14]. Many alternative hypotheses are proposed [15–20], and although generally based on observations, most are speculative by definition, limiting their wide acceptance.

Where Progress has been Made

The Human Genome Project and other large-scale multinational programs have profoundly transformed biomedical research, introducing ever more sophisticated and powerful

¹ The members of The Endometriosis Initiative Group are listed at the end of the article.

Corresponding authors: (On behalf of the Endometriosis Initiative Group) Michel Canis, M.D., Ph.D., Department of Obstetrics Gynecology and Reproductive Medicine, CHU Clermont Ferrand, Clermont Ferrand, France, Email: mcanis@chu-clermontferrand.fr. Sun-Wei Guo, Ph.D., Shanghai Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200011, China, Email: hoxa10@outlook.com

tools: microarrays, proteomics, metabolomics, metagenomics, next-generation sequencing, and, recently, single-cell technologies and spatial transcriptomics. Nearly every aspect of endometriosis has been explored or investigated with these technologies, albeit often with limited sample sizes and confounded controls.

Substantive clinical, cellular, or molecular differences between patients with and without endometriosis are increasingly reported, as well as differences in groups of patients with endometriosis. During the endometriosis meetings held in Edinburgh, Abu Dhabi, and Rome in the spring of 2023, numerous new findings were presented. These included the identification through genome-wide association studies of some 42 loci predisposing women to endometriosis, a 3-fold increase from previous studies [21]. Such results hold promise for the development of new diagnostic tools or newer targets for drug development or repurposing. Despite concerns [22], microRNA-based non-invasive tools are also entering the market, promising to change the way to diagnose endometriosis [23,24]. The possible role of microbiota in the development of endometriosis has been recently reported, suggesting that the role of infection in disease etiology should be taken seriously and further investigated [25]. These findings are obvious reasons for hope in patients with endometriosis worldwide. They provide the rationale for funding this fast-expanding research field, particularly when more sophisticated and powerful technologies, such as organoids, tissue engineering, and single-cell sequencing, are used increasingly for the studies in endometriosis [26–29].

However, closer scrutiny of these seemingly exciting discoveries leaves significant concerns. First, the reports of microRNA-based biomarkers and the putative causal link between microbial agents and endometriosis are yet to be independently validated [22]. Second, despite years of work involving tens of thousands of patients, the 42 loci identified only explain approximately 2% of disease variance [21], meaning the vast majority of causes (>98%) are not accounted for by hereditary factors, although improved understanding of disease risk according to subphenotypes might offer promise. Regardless, research requires reconciliation of genetic susceptibility and increasingly evident mismatch between evolutionary legacy and modern society [30–33] and for the contribution of in utero developmental factors and environmental insults to disease pathogenesis and pathophysiology [34]. Such technological advancements provide incremental knowledge and may possibly significantly improve patients' lives in the future, but to date have not led to a sweeping and revolutionary breakthrough in insight into endometriosis pathophysiology, leaving our understanding of the disease still limited.

We need fundamental changes in the ways we observe and interpret clinical, imaging, surgical, and pathologic data and all research (whatever the research technique used) data that are acquired. In our opinion, if there is no change in the way we conceptualize the disease, no matter how much more data

we accumulate and/or how we acquire these data, it will add little to our understanding. We may not need to understand the disease causality to find new treatments, drugs, or diagnostic tools. For instance, placebo-controlled studies of laparoscopic surgery informed us that recurrence of pain within 6 months probably has nothing to do with the development of de novo lesions but rather signifies the end of the placebo effect [35,36]. Therefore, repeated surgery shortly after a previous unsuccessful one is unjustified with multiple medical and surgical randomized controlled trials [37], reporting very similar results in this regard.

A Time for Reflection and Re-examination

Any and all new research theories regarding endometriosis should be developed, discussed, and scrutinized at the outset, given that no matter how fast a car travels, it will never reach its destination if going in the wrong direction. The beginning of the genomic era 20 years ago brought with it great hope and anticipation [38], especially with the reporting of the first genome-wide study [39]. This approach is particularly attractive, given that disease pathogenesis does not need to be known and it was predicted that it would radically transform diagnosis and treatment. Unfortunately, it turned out to be far more complicated than anticipated.

To date, basic science research has been too scant to substantively improve clinical outcomes in endometriosis, owing, at least in part, to historically poor funding of this field. Both clinicians and patients are frustrated by the repeated failure of clinical trials involving nonhormonal drugs and even antiestrogenic compounds—some rather surprisingly and unexpectedly [40,41]. Compared with more than 100 drugs approved for cancer since 1990, a paltry 3 (namely gonadotropin-releasing hormone agonists, dienogest, and gonadotropin-releasing hormone antagonists) have been approved for endometriosis. Furthermore, none of these drugs that induce amenorrhea were based on modern molecular and/or genomic approaches with specific targets identified. The disappointing stagnation in drug development is palpable among clinicians [42] and patients who often voice considerable dissatisfaction with the currently available hormonal drugs to treat endometriosis [43].

We recognize that major breakthroughs in science or medicine are unpredictable and do not occur overnight, with the translation of basic science discoveries to tangible clinical benefits often long and arduous. Hence, these frustrations may not be fully justified, given that the field is progressing, and 40 years may still be considered too short to achieve desirable improvements.

Drawing from the roller-coaster experience during these 40 years, it is the conviction of this group that, to transform the science around endometriosis, we need alternatives to the commonly accepted hypotheses and/or new ways to investigate the current ones. This must be accompanied by more expeditious, well-planned, and well-funded clinical trials for safety and efficacy. An alternative to the hand-

Table 1

List of questions by category

Category	Questions
Etiology/pathogenesis	<p>What causes endometriosis?</p> <p>When, how, and why does the disease begin?</p> <p>Where do endometriosis cells originate?</p> <p>What is/are the cell(s) of origin of endometriosis?</p>
Natural history	<p>Is endometriosis a singular disease entity or should it be considered as a syndrome?</p> <p>Is the disease progressive?</p> <p>If progressive, how can this be quantified and what factors contribute to disease progression?</p> <p>Is endometriosis a continuous disease state or can it occur intermittently?</p> <p>Does presence of endometriosis have an underlying permanent disease state?</p> <p>Can the various phenotypes (clinical, anatomic, histologic. . .) observed be explained?</p> <p>Are all lesions observed in a patient related to the same cause ?</p> <p>Why are symptoms so variable between women?</p> <p>Could or should the clinical management be adapted according to the disease phenotypes (clinical and/or surgical) found in a particular patient?</p>
Pathophysiology	<p>How does endometriosis cause or relate to pain and/or associated symptoms, subfertility, and pregnancy outcomes?</p> <p>How do different subtypes of endometriosis affect pain and/or associated symptoms severity, subfertility, and pregnancy outcomes?</p> <p>What are the mechanisms underlying persistence or recurrence?</p> <p>Is there any novel way to prevent endometriosis, or at least to mitigate the risk of the disease and of recurrence?</p>
Clinical management	<p>Could or should the clinical management be adapted according to the disease phenotypes (clinical and/or surgical) found in a particular patient?</p>
Miscellaneous; outcome measures	<p>What are the core outcome measures for successful management of endometriosis?</p>

waving saying that “endometriosis is a chronic, inflammatory, multifactorial, progesterone resistant, and complex disease” is urgently needed. Given that the adjective “complex” means “hard to separate, analyze, or solve” (Webster Dictionary), using the word “complex” may be a tacit concession that we are unlikely to find an explanation for the cause of the disease and to significantly improve our care for symptomatic patients.

An alternative is also needed to the very often used proposition that “common sense tells us that endometriosis should be a progressive disease beginning with menarche and menstrual bleeding [44],” given that age and the severity of the disease are unrelated [44]. Retrograde menstruation, stem cells, embryologic remnants, and/or metastases could occur or possibly occur in all women, yet endometriosis does not. Consequently, we need accurate mechanistic explanations rather than merely a “just-so” story, to understand why and how the disease begins and progresses to find effective therapeutic interventions.

To achieve this goal, we may need to move away from our “comfort zone” and not become complacent.

New and Innovative Theories/Hypotheses are Needed

Hopefully, new theories/hypotheses will be able to fully answer at least one of the questions as listed (Table 1).

Obviously, more questions will be added to this initial list. We suggest that a proposed theory/hypothesis would be summarized in 2000 words with 1 page for references and 1 page for proposed clinical and/or basic research studies, designed to either confirm or refute the hypothesis.

All endometriosis researchers are encouraged to focus on addressing one or more of the questions listed earlier when conceiving, designing, and executing endometriosis studies and to collaborate with those in related and nonrelated disciplines to broaden the lens through which disease is seen.

Prerequisites for a Good Theory

Although there is no shortage of hypotheses or speculations on the pathogenesis and pathophysiology of endometriosis, what is truly needed must be novel, innovative, and perhaps disruptive theories that may provide an explicit explanation of the causes of endometriosis. As Werner Heisenberg has stated, “what we observe is not nature itself, but nature exposed to our method of questioning.”

A good theory should satisfy at least 3 basic requirements [45]:

1. The theory should explain most, if not all, existing observations about the pathogenesis of endometriosis in at least a substantial and identifiable subset of patients;

the theory may also account for why groups of patients may be different.

2. The theory ought to be falsifiable, meaning that it can be proven or refuted by experimentation. This requirement distinguishes a theory from a dogma. Indeed, a theory, however good or comprehensive, should be amenable to scientific tests and scrutiny even if this is not immediately accessible, as illustrated the case of the quantum mechanics studies performed by the 2022 physics Nobel prize laureates that confirmed hypotheses proposed several decades before. Medical examples include the finding of causative relationships between *Helicobacter pylori* infection and stomach cancer [46] and the more recently determined causation of previous infection with Epstein-Barr virus and the development of multiple sclerosis [47,48].
3. The theory should be able to make useful predictions that can be used to guide our future scientific query, development of new therapies or clinical management.

Making Endometriosis History

This group cordially invites everyone to join us in collectively solve all the many unanswered questions. Despite decades of research, endometriosis is still enigmatic. This is unsatisfactory and stressful to every patient. Innovative, even disruptive and risky, ideas, together with worldwide collaborations, are essential to change this situation. If there is no change, there is the real and unsettling prospect that the current questions will remain unsolved in 2 decades from now. Our patients deserve greater incremental progress than has been made up to the present.

We must state that we have genuine and deep respect for the tremendous, highly original, and long-term research efforts that have been conducted in the last 40 years. The results of these efforts and the technological advancements they have promoted have laid a foundation for the future. Could these efforts have paid off more profitably if guided by different and/or more structured theories? That will always be unknown, but perhaps it is high time for a drastic change in the thinking we have used when generating new hypotheses.

Challenges Ahead

Any new approach should take into account that not all the patients have the same disease, as suggested by the large standard deviations reported in many studies. Hypotheses that generate studies could be based on clinically, imaging, surgically, and/or histologically confirmed endometriosis cases, preferably with longitudinal follow-up incorporating metadata to investigate the association of emerging results with better characterized detailed disease phenotypes, including minimal or even occult disease. Challenges acknowledged include the evidence that the rising number of genetic loci that collectively account for only a minuscule

portion of disease variance, but may impact on specific disease forms. In addition, many women without endometriosis may carry one or more risk alleles, making the diagnosis, screening, or drug development more challenging. Similarly, environmental contributions to the disease—be it in utero, neonatal, or developmental—are challenging to investigate because of their complexity, but cannot be ignored as future possibilities for disease modification or even prevention. The detailed anatomical classifications, clearly defined measures, and comprehensive approaches for gathering, collecting, and evaluating specific signs and symptoms, association with comorbidities should be used whenever possible as suggested in the World Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonization Project [49]. Multiple classifications and measures will likely be needed given that none of those that are currently available seem universally applicable. There are currently significant limitations to our ability to recognize all endometriotic lesions and their progression/regression over time [50]. Control groups should consequently also be carefully evaluated, with comparisons performed according to the criteria used to define the population.

In conclusion, this group proposes that radically different approaches are needed. Indeed, using again and again the same approach, which has provided at best limited success, and hoping things will get better are counterintuitive if not futile. Moreover, imagination will be an absolute necessity, when conceiving novel and impactful theories on endometriosis accounting for all the data and knowledge currently available.

After the publication of this call, a dedicated repository website (<https://endo-theories.org>) will be created to publish all submitted theories and also provide a forum for open discussion, capitalizing on the fact that a less formal publication site is more open to new ideas and new theories and can be a chat room for open discussion to more physicians and/or scientists. This website, accessible by everyone, will be designed and maintained by the Endometriosis Initiative Group that will be in charge of reviewing the proposed theories and will moderate the discussions about the proposals. The Endometriosis Initiative Group will be open to any researcher interested to join the initiative. Anonymous comments or proposals will not be accepted. All are invited to contribute so that future generations of clinicians do not continue to mouth the platitudes that have plagued us for decades. The initial website design and hosting expenses are covered by one of the authors (M.C.), with future crowd funding proposed to cover future website maintenance costs.

1. Members of the Endometriosis Initiative Group

Jason Abbott (UNSW Sydney, Australia), Mauricio S Abrao (Universidade de Sao Paulo, Brazil), Moamar Al-Jefout, (United Arab Emirates University, UAE), Mohamed Bedaiwy, (The University of British Columbia, Vancouver, Canada), Giuseppe Benagiano, (“Sapienza” University of

Rome, Italy), Katherine A. Burns, (University of Cincinnati College of Medicine, Ohio, U.S.A), Michel Canis, (CHU Clermont Ferrand, University Clermont Auvergne, France), Francisco Carmona (Universitat de Barcelona, Spain), Charles Chapron, (Université Paris-Cité, Faculté de Santé, Faculté de Médecine Paris-Centre, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Paris Centre (HUPC), Centre Hospitalier Universitaire Cochin, Service de Gynécologie Obstétrique II et Médecine de la Reproduction, Paris, France), Hilary O. D. Critchley, (University of Edinburgh, UK), Dominique de Ziegler (Université de Paris Ouest, France), Tommaso Falcone (Women's Health Institute, Cleveland Clinic, Cleveland, Ohio, USA), Asgerally Fazleabas (Michigan State University, Grand Rapids, Michigan, USA), Simone Ferrero (University of Genova, Italy) Juan A. Garcia-Velasco, (Rey Juan Carlos University, Madrid, Spain), Caroline Gargett (Hudson Institute of Medical Research and Monash University, Melbourne, Australia), Erin Greaves (University of Warwick, Coventry, UK), Linda G. Griffith (Massachusetts Institute of Technology, USA), Sun-Wei Guo (Fudan University, Shanghai, China), Marwan Habiba (University of Leicester; Leicester Royal Infirmary, UK), Tasuku Harada (Tottori University Hospital, Tottori, Japan), Mary Louise Hull (Robinson Research Institute, University of Adelaide, Australia), Keith B Issacson (Newton-Wellesley Hospital, Newton, Massachusetts, USA), Neil P. Johnson (Flinders University, Adelaide, Australia), Yuval Kaufman (The Lady Davies Carmel Medical Center, Haifa, Israel), Khaleque N. Khan (Kyoto Prefectural University of Medicine, Japan), Mee-Ran Kim (The Catholic University of Korea, Seoul, Republic of Korea), Philippe A. Koninckx (University Hospital Gasthuisberg, Catholic University, Leuven, Belgium), Bruce A. Lessey (Atrium Health Wake Forest Baptist, Winston Salem, North Carolina, USA), Dan Martin (University of Tennessee Health Science Center, Memphis, USA), Sachiko Matsuzaki (CHU Clermont-Ferrand; Université Clermont Auvergne, France), Gita Mishra (University of Queensland, Brisbane, Australia), Yutaka Osuga (The University of Tokyo, Japan), Felice Petraglia (University of Florence, Careggi University Hospital, Italy), Alexander Popov (Moscow Regional Scientific Research Institute of Obstetrics and Gynecology, Russian Federation), Horace Roman (IFEMEndo, Clinique Tivoli-Ducos, Bordeaux, France), Andrea Romano (Maastricht University Medical Centre, Netherlands), Philippa Saunders (The University of Edinburgh, UK), Tamer Seckin (Lenox Hill Hospital, Northwell Health/Zucker School of Medicine, New York, USA), Edgardo Somigliana (Università degli Studi and Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy), Hugh S. Taylor (Yale School of Medicine, New Haven, Connecticut, USA), Robert N. Taylor[†] (University at Buffalo, USA), Paolo Vercellini (Università degli Studi and Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy), Paola Vigano (Infertility Unit,

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy)

[†]Pr RN Taylor passed away after approving the final draft of the paper.

Declaration of Competing Interest

Jason Abbott has received, for his research group, grants from the Australian Government, the Australian Gynecologic Endoscopy Society, and the Country Women's Association of NSW. He received personal consulting fees from Hologic, Vifor, and Gedeon Richter. He received payment for presentations from MSD and Hologic and support for travel from Hologic. He was involved in advisory board for Hologic, Vifor, and Gedeon Richter. He is past president of AGES, Chair of the Australian Endometriosis Guideline Committee, and Past Chair of Endometriosis Australia. Moamar Al-Jefout is President of the Asian Society of Endometriosis and Adenomyosis. Mohamed Bedaiwy received grants from the Canadian Institute of Research and from Ferring Pharmaceutica and honoraria from Abbvie, Ferring, and Pfizer. Katherine A. Burns is an associate editor of *Biology of Reproduction* and has received research funding from Ferring. Michel Canis is the president elect of the American Association of Gynecologic Laparoscopists (AAGL). He receives travel expenses coverage from AAGL. He also received travel expenses coverage for the 2023 World Congress on Endometriosis meeting from Gedeon Richter. Francisco Carmona has received consulting fees from Adamed, Gedeon Richter, Organon, and Theramex. Charles Chapron has received consulting fees and honoraria for lectures from Gedeon Richter and honoraria from Besins. He is member of the Society for Endometriosis and Uterine Disorder. Hilary Critchley has received clinical research support for laboratory consumables and staff from Bayer and received royalties from UpToDate for an article on abnormal uterine bleeding. She is an Associate Editor for *Physiological Reviews*. Asgerally Fazleabas has received support from the National Institute of health (United States). Simone Ferrero is Vice Chair of the Endometriosis Special interest group of the American Society for Reproductive Medicine (ASRM), Immediate Past Chair of the Fibroid Special Interest group of ASRM, and member of Member of the ISUOG Courses Task Force. Juan Garcia Garcia-Velasco received grants from Merck, Gedeon Richter, and Ferring and honoraria for presentation from Ferring, Gedeon Richter, Organon, Merck, and Theramex. He is the co-Editor-in-Chief of *Reproductive BioMedicine Online*. Caroline Gargett receives a grant from the National Health and Medical Research Council (Australia) for her salary and research. She received grants for her institution from the US Department of Defense, the Medical Research Future Fund, and the CASS foundation. She is an unpaid member of the of Fondation pour la Recherche sur L'Endometriose France, Internat Sci Committee, Endo-Found (United States) Scientific Advisory Board, and Julia

Argyrou Endometriosis Centre at Epworth Research Committee. She is an unpaid director of National Stem Cell Foundation of Australia and Stem Cells Australia Ltd. She received honoraria and travel expenses coverage for an invited lecture from the Japan Society of Reproductive Medicine and for an invited review from *Journal of Obstetric and Gynaecologic Research*. Erin Greaves received grants from the Medical Research Council to support the University of Warwick. She received support from the World Endometriosis Society for payment of Hotel Fees. She is participating in the board of the World Endometriosis Society, the World Endometriosis Research Foundation, and Fondation pour la Recherche sur l'Endometriose. Dr. Guo is the co-Editor-in-Chief of *Journal of Endometriosis and Uterine Disorders* and a member of the Scientific Advisory Board of Heranova BioSciences and has provided consultancy advice to the company, as well as to Sound Bioventures, but these activities had no bearing on this work. Tasuku Harada received consulting fees from Nobel pharma and honorarium from ASKA pharmaceutical company and Fuji pharmaceutical company. Marwan Habiba has received research grants from Medical Research Future Fund and Health Department and honoraria from Ferring. She received support from Merck as sponsored speaker, provision on a patent submitted. She is involved in the advisory board of Fertilis, on the Medical Advisory Board for Endometriosis Australia, and of APIRE. She is president of ANZSREI. She is owner of Embrace Fertility IVF unit. Neil Philippe Johnson is a board member of ASPIRE and past president and board member of the World Endometriosis Society and has provided consultancy advice to Guerbet, Myovant Sciences, Abbott, and Gedeon Richter. He received honoraria from Guerbet, Myovant Science, and Abbott and support for travel from Guerbet and Myovant Sciences and participate on advisory board of Guerbet and Myovant Sciences. Yuval Kaufman has received honoraria for lectures from AbbVie pharmaceuticals, Conmed, Syqe, and Tzamal Medical. He is a consultant at Gynica, Ark Surgical, and Idan. Bruce Lessey has licensed technology for diagnostic biomarkers of endometriosis through Prisma Health, Greenville, SC. Dan Martin was paid an honoraria and was reimbursed for expenses for a presentation at the ASRM annual meeting in 2021; had expenses paid for a presentation at the 6th European Endometriosis Congress, Bordeaux; had expenses paid for a presentation at the Endo-Found annual meeting 2023; had expenses paid for the American College of obstetrics and gynecology annual meeting 2023 to represent the Endometriosis Foundation of America; had expenses paid for the AAGL 2023 annual meeting as a past president and to represent the Endometriosis Foundation of America; is a paid member of the Virginia Commonwealth University Institutional Review Board; and is an unpaid advisor to SLBST Pharma, Inc, a company repurposing anti-inflammatory medicine for endometriosis. Sachiko Matsuzaki is Associate Editor: Human Reproduction Update and Academic Editor: Plos One. Gita

Mishra is funded by the Australian Health and Medical Research Council Investigator grant and received grants through a contract from the Australian Government Department of Health and Aged Care to run the Australian Longitudinal Study on women's health. Alexander Popov is a Board member of the Asian Society of Endometriosis and adenomyosis and vice president of the Russian Association of Human Reproduction. Horace Roman has received consulting fees from Olympus, Johnson and Johnson, and Intuitive Surgical. He received honoraria from BBraun and Nordic Pharma. Andrea Romano is the member of the Executive Committee of the *European Society of Human Reproduction and Embryology*. Edgardo Somigliana has received honoraria for lectures from Ibsa and Gedeon Richter, handles grants research from Ferring and Ibsa, and is the Editor-in-chief of *Human Reproduction Open*. Philippa Saunders has received funding from the UK Medical Research Council and the European Union (IMI and RISE schemes). The University of Edinburgh has received the fees for her consultations with Gesytna, Benevolent AI, and Kynos. She is Treasurer of the World Endometriosis Society. Hugh Taylor has received grants from AbbVie to support Yale University. Robert Taylor had received grants from the National Institute of Child Health and Human Development. He received consulting fees from Mitsubishi, DotLab Inc, and Bayer AH. He participated in the advisory board for DotLab Inc. Paolo Vercellini has received royalties from Wolters Kluwer for chapters on endometriosis management in the clinical decision support resource UpToDate and serves in the editorial board of *Human Reproduction*, *Journal of Obstetrics and Gynecology Canada*, *Acta Obstetrica and Gynecologica Scandinavica*, *Journal of Endometriosis and Uterine Disorders*, *Journal of Endometriosis and Pelvic Pain Disorders*, and *Italian Journal of Obstetrics and Gynecology*. Paola Vigano is the co-Editor-in-Chief of the *Journal of Endometriosis and Uterine Disorders*. The other authors declare that they have no conflict of interest.

References

1. Simpson JL, Elias S, Malinak LR, Buttram VC Jr. Heritable aspects of endometriosis. I. Genetic studies. *Am J Obstet Gynecol*. 1980;137:327-331.
2. Halme J, Becker S, Wing R. Accentuated cyclic activation of peritoneal macrophages in patients with endometriosis. *Am J Obstet Gynecol*. 1984;148:85-90.
3. Jänne O, Kauppila A, Kokko E, Lantto T, Rönnerberg L, Vihko R. Estrogen and progesterin receptors in endometriosis lesions: comparison with endometrial tissue. *Am J Obstet Gynecol*. 1981;141:562-566.
4. Steele RW, Dmowski WP, Marmer DJ. Immunologic aspects of human endometriosis. *Am J Reprod Immunol (1980)*. 1984;6:33-36.
5. Wu Y, Halverson G, Basir Z, Strawn E, Yan P, Guo SW. Aberrant methylation at HOXA10 may be responsible for its aberrant expression in the endometrium of patients with endometriosis. *Am J Obstet Gynecol*. 2005;193:371-380.
6. Wu Y, Strawn E, Basir Z, Halverson G, Guo SW. Promoter hypermethylation of progesterone receptor isoform B (PR-B) in endometriosis. *Epigenetics*. 2006;1:106-111.

7. Du H, Taylor HS. Contribution of bone marrow-derived stem cells to endometrium and endometriosis. *Stem Cells*. 2007;25:2082–2086.
8. Gargett CE. Uterine stem cells: what is the evidence? *Hum Reprod Update*. 2007;13:87–101.
9. Guo SW, Wu Y, Strawn E, et al. Genomic alterations in the endometrium may be a proximate cause for endometriosis. *Eur J Obstet Gynecol Reprod Biol*. 2004;116:89–99.
10. Suda K, Nakaoka H, Yoshihara K, et al. Clonal expansion and diversification of cancer-associated mutations in endometriosis and normal endometrium. *Cell Rep*. 2018;24:1777–1789.
11. Anglesio MS, Papadopoulos N, Ayhan A, et al. Cancer-associated mutations in endometriosis without cancer. *N Engl J Med*. 2017;376:1835–1848.
12. Wattiez A, Schindler L, Ussia A, et al. A proof of concept that experience-based management of endometriosis can complement evidence-based guidelines. *Facts Views Vis Obgyn*. 2023;15:197–214.
13. Sampson JA. Peritoneal endometriosis due to the menstrual dissemination of endometrial tissue into the peritoneal cavity. *Am J Obstet Gynecol*. 1927;14:422–469.
14. Sampson JA. Metastatic or embolic endometriosis, due to the menstrual dissemination of endometrial tissue into the venous circulation. *Am J Pathol*. 1927;3: 93–110.43.
15. Leyendecker G, Wildt L, Laschke MW, Mall G. Archimetrosis: the evolution of a disease and its extant presentation: pathogenesis and pathophysiology of archimetrosis (uterine adenomyosis and endometriosis). *Arch Gynecol Obstet*. 2023;307:93–112.
16. Quinn MJ. Endometriosis: the consequence of uterine denervation-reinnervation. *Arch Gynecol Obstet*. 2011;284:1423–1429.
17. Khan KN, Fujishita A, Hiraki K, et al. Bacterial contamination hypothesis: a new concept in endometriosis. *Reprod Med Biol*. 2018;17:125–133.
18. Canis M, Bourdel N, Houlle C, Gremeau AS, Botchorishvili R, Matsuzaki S. Trauma and endometriosis. A review. May we explain surgical phenotypes and natural history of the disease? *J Gynecol Obstet Hum Reprod*. 2017;46:219–227.
19. Guo SW. Cracking the enigma of adenomyosis: an update on its pathogenesis and pathophysiology. *Reproduction*. 2022;164:R101–R121.
20. Koninckx PR, Ussia A, Adamyan L, Wattiez A, Gommel V, Martin DC. Pathogenesis of endometriosis: the genetic/epigenetic theory. *Fertil Steril*. 2019;111:327–340.
21. Rahmioglu N, Mortlock S, Ghiasi M, et al. The genetic basis of endometriosis and comorbidity with other pain and inflammatory conditions. *Nat Genet*. 2023;55:423–436.
22. Viganò P, Vercellini P, Somigliana E, et al. I'm looking through you": what consumers and manufacturers need to know about non-invasive diagnostic tests for endometriosis. *J Endometr Uter Dis*. 2023;2:100031.
23. Moustafa S, Burn M, Mamillapalli R, Nematian S, Flores V, Taylor HS. Accurate diagnosis of endometriosis using serum microRNAs. *Am J Obstet Gynecol*. 2020;223:557.e1–557.e11.
24. Bendifallah S, Suisse S, Puchar A, et al. Salivary MicroRNA Signature for Diagnosis of Endometriosis. *J Clin Med*. 2022;11.
25. Muraoka A, Suzuki M, Hamaguchi T, et al. Fusobacterium infection facilitates the development of endometriosis through the phenotypic transition of endometrial fibroblasts. *Sci Transl Med*. 2023;15:eadd1531.
26. Symons LK, Miller JE, Kay VR, et al. The immunopathophysiology of endometriosis. *Trends Mol Med*. 2018;24:748–762.
27. Bae SJ, Jo Y, Cho MK, et al. Identification and analysis of novel endometriosis biomarkers via integrative bioinformatics. *Front Endocrinol (Lausanne)*. 2022;13:942368.
28. Perricos A, Husslein H, Kuessel L, et al. Does the use of the "Proseek® multiplex inflammation I Panel" demonstrate a difference in local and systemic immune responses in endometriosis patients with or without deep-infiltrating lesions? *Int J Mol Sci*. 2023;24.
29. Cousins FL, McKinnon BD, Mortlock S, et al. New concepts on the etiology of endometriosis. *J Obstet Gynaecol Res*. 2023;49:1090–1105.
30. Mumusoglu S, Hsueh AJW. Is endometriosis due to evolutionary maladaptation? *Reprod Biomed Online*. 2024;48:103695.
31. Vercellini P, Bandini V, Viganò P, Ambruoso D, Cetera GE, Somigliana E. Proposal for targeted, neo-evolutionary-oriented secondary prevention of early-onset endometriosis and adenomyosis. Part II: medical interventions. *Hum Reprod*. 2024;39:18–34.
32. Vercellini P, Bandini V, Viganò P, Di Stefano G, Merli CEM, Somigliana E. Proposal for targeted, neo-evolutionary-oriented, secondary prevention of early-onset endometriosis and adenomyosis. Part I: pathogenic aspects. *Hum Reprod*. 2024;39:1–17.
33. Guo SW. How do women get endometriosis? *Reprod Biomed Online*. 2023 Nov 10. [Epub ahead of print].
34. Dinsdale N, Nepomnaschy P, Crespi B. The evolutionary biology of endometriosis. *Evol Med Public Health*. 2021;9:174–191.
35. Sutton CJ, Ewen SP, Whitelaw N, Haines P. Prospective, randomized, double-blind, controlled trial of laser laparoscopy in the treatment of pelvic pain associated with minimal, mild, and moderate endometriosis. *Fertil Steril*. 1994;62:696–700.
36. Abbott J, Hawe J, Hunter D, Holmes M, Finn P, Garry R. Laparoscopic excision of endometriosis: a randomized, placebo-controlled trial. *Fertil Steril*. 2004;82:878–884.
37. Hans Evers JL. Is adolescent endometriosis a progressive disease that needs to be diagnosed and treated? *Hum Reprod*. 2013;28:2023.
38. Zondervan KT, Cardon LR, Kennedy SH. The genetic basis of endometriosis. *Curr Opin Obstet Gynecol*. 2001;13:309–314.
39. Nyholt DR, Low SK, Anderson CA, et al. Genome-wide association meta-analysis identifies new endometriosis risk loci. *Nat Genet*. 2012;44:1355–1359.
40. Guo SW. An overview of the current status of clinical trials on endometriosis: issues and concerns. *Fertil Steril*. 2014;101:183–190.e4.
41. Guo SW, Groothuis PG. Is it time for a paradigm shift in drug research and development in endometriosis/adenomyosis? *Hum Reprod Update*. 2018;24:577–598.
42. Vercellini P, Crosignani P, Somigliana E, Viganò P, Frattaruolo MP, Fedele L. Waiting for Godot': a commonsense approach to the medical treatment of endometriosis. *Hum Reprod*. 2011;26:3–13.
43. Burla L, Kalaitzopoulos DR, Metzler JM, Scheiner D, Imesch P. Popularity of endocrine endometriosis drugs and limited alternatives in the present and foreseeable future: A survey among 1420 affected women. *Eur J Obstet Gynecol Reprod Biol*. 2021;262:232–238.
44. Savaris RF, Nichols C, Lessey BA. Endometriosis and the enigmatic question of progression. *J Endometriosis Pelvic Pain Disord*. 2014;6:121–126.
45. Hawking SW, Anderson JL. A brief history of time. *Physics Today*. 1988;41:115–117.
46. Houghton J, Wang TC. Helicobacter pylori and gastric cancer: a new paradigm for inflammation-associated epithelial cancers. *Gastroenterology*. 2005;128:1567–1578.
47. Farrell PJ. EBV and MS: the evidence is growing stronger. *Cell*. 2023;186:5675–5676.
48. Vietzen H, Berger SM, Kühner LM, et al. Ineffective control of Epstein-Barr-virus-induced autoimmunity increases the risk for multiple sclerosis. *Cell*. 2023;186:5705–5718.e13.
49. Vitonis AF, Vincent K, Rahmioglu N, et al. World endometriosis research foundation endometriosis phenotype and biobanking harmonization project: II. Clinical and covariate phenotype data collection in endometriosis research. *Fertil Steril*. 2014;102:1223–1232.
50. Roman H, Merlot B, Forestier D, et al. Nonvisualized palpable bowel endometriotic satellites. *Hum Reprod*. 2021;36:656–665.